How Johnson & Johnson’s billion-dollar bet on NM26 could transform atopic dermatitis treatment
Johnson & Johnson (NYSE: JNJ) has successfully concluded its acquisition of Yellow Jersey, a division previously part of Numab Therapeutics, for a substantial $1.25 billion. This strategic move secures Johnson & Johnson the exclusive global rights to NM26, a pioneering bispecific antibody set to advance into Phase 2 trials for treating atopic dermatitis (AD). NM26 […]